Financing - May 26, 2026
Spago Nanomedical resolves on a rights issue of approximately SEK 16 million
The Board of Directors of Spago Nanomedical has resolved on a new issue of shares with preferential rights for the company’s existing shareholders of approximately SEK 16 million before issue costs.
Clinical Trials - May 25, 2026
Sobi announces positive Phase 3 results
Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.
Financing - May 22, 2026
Neobiomics receives investment from HealthCap
The company has announced an investment led by HealthCap, and conjunction with this capital infusion, Neobiomics strengthens its board with the appointment of a new director, Mårten Steen, Managing Partner at HealthCap.
Collaboration - May 20, 2026
Western Sweden unites to boost life sciences competitiveness
Industry, academic, and public stakeholders will join forces in a new council aimed at accelerating the region's life science development.
Clinical Trials - May 19, 2026
Orexo announces positive outcome from an in-vivo study
Orexo has announced positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology.
Agreement - May 19, 2026
Hansa Biopharma in EUR 115 million licensing agreement
Hansa Biopharma and SERB S.A. have announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.
